Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00092703
NCT00092703
Completed
Phase 3

A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis

Organon and Co0 sites6,000 target enrollmentJune 27, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOsteoarthritis
DrugsMK0663, etoricoxibComparator: Diclofenac sodium

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Osteoarthritis
Sponsor
Organon and Co
Enrollment
6000
Primary Endpoint
Discontinuations due to clinical and laboratory gastrointestinal adverse experiences during a 1 year treatment period.
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study is to compare the gastrointestinal tolerability of an investigational drug to an approved drug in the treatment of osteoarthritis during one year treatment period.

Detailed Description

The duration of treatment is 12 months.

Registry
clinicaltrials.gov
Start Date
June 27, 2002
End Date
November 1, 2003
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Osteoarthritis of the knee, hip, hand or spine which requires the use of medications for pain relief

Exclusion Criteria

  • •Known allergies to the study drugs

Outcomes

Primary Outcomes

Discontinuations due to clinical and laboratory gastrointestinal adverse experiences during a 1 year treatment period.

Similar Trials

Completed
Phase 2
A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)Smoking
NCT00109135Merck Sharp & Dohme LLC300
Completed
Phase 2
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic ConstipationConstipation
NCT00306748Ironwood Pharmaceuticals, Inc.40
Completed
Phase 2
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With SchizophreniaSchizophrenia
NCT01377233H. Lundbeck A/S46
Completed
Phase 3
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPsoriasis
NCT04761627Amgen494
Completed
Phase 1
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative ColitisUlcerative Colitis
NCT01759056Avaxia Biologics, Incorporated33